EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma

Philippe Barthélémy, Pascale Dutailly, Bryan Qvick, Valerie Perrot, Elena Verzoni

Future Oncology · 2024

DOI: 10.2217/fon-2023-0353 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Philippe Barthélémy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Cancérologie Strasbourg Europe, 17 Rue Albert Calmette, Strasbourg, 67200, France. Hauptthemen laut MEDLINE: Anilides, Antineoplastic Agents, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ipsen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cabozantinib plus nivolumab was approved as a first-line (1L) treatment for advanced renal cell carcinoma (aRCC) following the CheckMate 9ER trial. CaboCombo (ClinicalTrials.gov identifier: NCT05361434) is a non-interventional study designed to evaluate the effectiveness and tolerability of cabozantinib plus nivolumab in a real-world setting. Overall, 311 patients with clear-cell aRCC receiving 1L cabozantinib plus nivolumab will be recruited from at least 70 centers in seven countries worldwide. The primary end point is overall survival at 18 months. Secondary end points include progression-free survival, objective response rate, safety, patterns of treatment, subsequent anticancer therapies and quality of life. CaboCombo will provide real-world evidence on the characteristics, treatment sequences, and outcomes of patients with aRCC receiving 1L cabozantinib plus nivolumab. Renal cell carcinomas (RCC) are cancers that grow in the kidneys. Clear-cell RCC is the most common type reported in almost three quarters of patients. RCC tumors become advanced if they grow and spread to other parts of the body. In a clinical trial called CheckMate 9ER, a combination of two drugs called cabozantinib and nivolumab improved survival compared with a drug called sunitinib in patients with advanced clear-cell RCC who had not received any previous treatments. In CheckMate 9ER, cabozantinib plus nivolumab also reduced the size and slowed the spread of tumors compared with sunitinib. However, clinical trials only allow certain patients to participate under strict treatment conditions and so do not provide information on how a treatment will work in all patients. Researchers therefore carry out additional studies to gather extra information from real-world clinical practice. CaboCombo is a study that will look at how well cabozantinib plus nivolumab stops tumors from growing and spreading, the side effects of the drugs, and also how the drugs are used by doctors. It is an observational study, which means that researchers will observe all patients and doctors using the treatment but they will not intervene. The aim of the study is to gather information that will help doctors make treatment decisions for their patients. This article describes how the CaboCombo study will be carried out and the information it will give the researchers. The results will help physicians make decisions on the best treatment option for patients. Clinical Trial Registration: NCT05361434 (ClinicalTrials.gov).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesAntineoplastic AgentsCarcinoma, Renal CellKidney NeoplasmsPyridinesHumansClinical Trials, Phase IV as TopicNivolumabProspective StudiesQuality of Life

Stichwörter der Autor:innen

cabozantinibcheckpoint inhibitornivolumabrenal cell carcinomatyrosine kinase inhibitor

Substanzen

AnilidesAntineoplastic AgentscabozantinibNivolumabPyridines

Autor:innen und Institutionen

  • Institut de Cancérologie Strasbourg Europe, 17 Rue Albert Calmette, Strasbourg, 67200, France.
  • Ipsen, 65 Quai Georges Gorse, Boulogne-Billancourt, 92100, France.
  • Ipsen, Einsteinstraße 174, München, 81677, Germany.
  • Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, Milano, 20133, Italy.

Förderung

  • Ipsen

Zitieren

APA

Barthélémy, P., Dutailly, P., Qvick, B., Perrot, V., & Verzoni, E. (2024). CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma. Future Oncology. https://doi.org/10.2217/fon-2023-0353

Vancouver

Barthélémy P, Dutailly P, Qvick B, Perrot V, Verzoni E. CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma. Future Oncology. 2024. doi:10.2217/fon-2023-0353

BibTeX
@article{Barthlmy2024,
  author = {Barthélémy, Philippe and Dutailly, Pascale and Qvick, Bryan and Perrot, Valerie and Verzoni, Elena},
  title = {CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2023-0353}
}
Kostenlos starten →